-+ 0.00%
-+ 0.00%
-+ 0.00%

Ardelyx reports real-world study shows lower GI-related healthcare visits after IBSRELA start in IBS-C patients

PUBT·10/12/2026 12:04:01
Listen to the news
Ardelyx reports real-world study shows lower GI-related healthcare visits after IBSRELA start in IBS-C patients
  • Ardelyx disclosed real-world study results on IBSRELA use in adults with IBS-C, presented at the American College of Gastroenterology meeting.
  • Analysis found gastrointestinal-related healthcare visits fell meaningfully in the year following treatment initiation versus the prior year.
  • Separate posters scheduled for Oct. 13 will outline a Phase 3 trial design for tenapanor in chronic idiopathic constipation.
  • Additional research to be presented links higher IBS-C symptom burden with poorer quality of life in US adults.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ardelyx Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610120801PRIMZONEFULLFEED9843817) on October 12, 2026, and is solely responsible for the information contained therein.